financetom
Business
financetom
/
Business
/
Discover Financial fourth-quarter profit jumps on lower loan loss provisions
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Discover Financial fourth-quarter profit jumps on lower loan loss provisions
Jan 22, 2025 2:49 PM

(Reuters) - U.S. credit card issuer Discover Financial posted a more than threefold increase in fourth-quarter profit on Wednesday, helped by a drop in provisions for credit losses and a rise in interest income.

The Federal Reserve's decision to lower interest rates and hopes of a soft landing for the economy helped ease lenders' concerns about potential credit defaults in 2025.

Discover's provision for credit losses fell to $1.20 billion in the quarter ended Dec. 31 from about $1.91 billion in the year-ago period.

Strong consumer spending has helped credit card-focused lenders rake in a higher income from interest.

Riverwoods, Illinois-based Discover recorded net interest income of $3.63 billion for the fourth quarter, up nearly 4.7% from the same quarter last year.

"Discover's fourth quarter results capped off a successful 2024 as loan growth, margin expansion, and credit improvement led to strong financial performance," said interim CEO Michael Shepherd in a statement.

Capital One Financial ( COF ), which is acquiring Discover for $35.3 billion in an all-stock deal, also recorded a jump in fourth-quarter profit on Tuesday, helped by higher interest income.

The merger between Capital One and Discover would form the sixth-largest U.S. bank by assets and a U.S. credit card behemoth.

Discover posted a net income of $1.29 billion, or $5.11 per share, in the October-to-December period, compared to $366 million, or $1.45 per share, in the year ago period.

Shares of the company, which jumped 54% in 2024, were up marginally in trading after the bell.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved